1186607-05-5

Basic information

• Product Name: Raf inhibitor a
• Synonyms: Raf inhibitor a
• CAS NO: 1186607-05-5
• Molecular Weight: 425.416
• Mol File: 1186607-05-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Raf inhibitor a(CAS DataBase Reference)
• NIST Chemistry Reference: Raf inhibitor a(1186607-05-5)
• EPA Substance Registry System: Raf inhibitor a(1186607-05-5)

Safety Data

• Hazardous Substances Data: 1186607-05-5(Hazardous Substances Data)

Upstream product

• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 
• 78686-79-0 methyl 2-chloro-5-bromonicotinate 
• 1186608-89-8 tert-butyl 3-methoxy-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-5-ylcarbamate 
• 1186609-74-4 3-methoxy-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-5-amine 
• 1186608-88-7 5-bromo-3-methoxy-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine 
• 1186608-87-6 5-bromo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-3-ol 
• 1086064-44-9 5-bromo-1H-pyrazolo[3,4-b]pyridin-3-ol 
• 1103234-56-5 2,6-difluoro-3-(propane-1-sulfonylamino)benzoic acid 
• 1186193-95-2 methyl 2,6-difluoro-3-(N-(propylsulfonyl)propylsulfonamido)benzoate 
• 84832-02-0 methyl 3-amino-2,6-difluorobenzoate 
• 84832-01-9 methyl 2,6-difluoro-3-nitrobenzoate 
• 13671-00-6 methyl 2,6-difluorobenzoate 
• 385-00-2 2,6-difluorobenzoic acid 
• 1186614-21-0 3-methoxy-5-nitro-1H-pyrazolo[3,4-b]pyridine 

Downstream Products

• 1422540-39-3 2,6-difluoro-N-(3-hydroxy-1H-pyrazolo[3,4-b]pyridine-5-yl)-3-(propylsulfonamido)benzamide 

Relevant articles and documents

Synthesis of 2,6-difluoro-N-(3-[11C]methoxy-1H-pyrazolo[3,4-b] pyridine-5-yl)-3-(propylsulfonamidio)benzamide as a new potential PET agent for imaging of B-RafV600E in cancers

The authentic standard 2,6-difluoro-N-(3-methoxy-1H-pyrazolo[3,4-b] pyridine-5-yl)-3-(propylsulfonamidio)benzamide was synthesized from 2,6-difluorobenzoic acid and 3-amino-5-hydroxypyrazole in 9 steps with 1% overall chemical yield. Direct desmethylation

PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.